Moderate to severe psoriasis patients usher in their gospel. The results of C5 a studypublished in the March 27 issue of the NEJM, confirmed that interleukin-17 receptorinhibitors Brodalumab safe and effective treatment of psoriasis. Clinical Phase II,double-blind, placebo-controlled, dose gradient study, the people of Saint LouisUniversity in Canada, Kim A. and the Papp Dr. the drug brodalumab (AMG 827)treatment of moderate to severe psoriasis efficacy and safety of C6orf108 were evaluated.
They were randomly assigned to the psoriasis area and severity index (PASI was thescore distribution of 0-72, with higher scores indicates that the illness is more severe)score above 12 points, and the psoriasis lesion surface area of at least 10% of patients receiving brodalumab (in the 1, 2, 4, 6, 8 and 10 weeks, 1 day, 70 mg, 140 mg or 210mg dose of CA1 treatment, or a monthly 280 mg) or placebo. The test confirmed brodalumabcan improve the first 12 weeks PASI score, PASI was at least 75% PASI was lesionsand at least 90% of lesions improved the proportion of CA10 patients improved, 12 weeks a static physician global score also improved.
The study randomly included in the 198 subjects. 12 weeks, patients receiving 70 mgbrodalumab treatment, the average PASI score improved 45.0% and the 140 mgbrodalumab treatment group the average improvement percentage was 86.3%, 280 mgbrodalumab treatment group the average improvement percentage was 76.0%, theplacebo treatment group each group compared with placebo was 16.0% (P <0.001). 12 weeks of the treatment group of CA12 140-mg brodalumab PASI score of 75% and 90% improvement in the proportion of patients were 77% and 72%,210-mg brodalumabtreatment group this value was 82% and 75% in the placebo group 0% (per treatment group and placebo group compared to both P <0.001). 70-mg, 140-mg of the 210-mgand the minimum residual rate of disease in a comprehensive evaluation of the 280-mg dose group, or complete clearance rate in each dose group were 26%, 85%, 80% and69% comfort dose group compared with 3% (compared with the placebo group, P <0.01). 210-mg brodalumab group and two cases of patients with neutropenia syndromebrodalumab treatment group is the most common adverse events were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection site rash (6 %)